Bisantrene
Based on 6 publication(s) in Google Scholar
Bisantrene is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene targets eukaryotic type II topoisomerases. Bisantrene is a substrate of MDR1.
For research use only. We do not sell to patients.
- Purity : 98.06%
- CAS No.: 78186-34-2
- Formula: C22H22N8
- Molecular Weight:398.46
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Bisantrene
MoreAll Topoisomerase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Topoisomerase II |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
0.34 μM
Compound: Bisantrene
|
Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line
Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line
|
[PMID: 9871638] |
| A549 | IC50 |
0.017 μM
Compound: 1
|
Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.
Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.
|
[PMID: 9371238] |
| HL-60 | IC50 |
0.3 μM
Compound: Bisantrene
|
Cell cytotoxicity was determined against human promyelocytic leukemia (HL60) cell line
Cell cytotoxicity was determined against human promyelocytic leukemia (HL60) cell line
|
[PMID: 9871638] |
| L1210 | IC50 |
0.049 μM
Compound: 1
|
Compound was tested for potency against multidrug-resistant murine leukemia L1210 cells
Compound was tested for potency against multidrug-resistant murine leukemia L1210 cells
|
[PMID: 9371238] |
| L1210 | IC50 |
3.2 μM
Compound: 1
|
Compound was tested for potency against multi drug resistant murine leukemia L1210 cells.
Compound was tested for potency against multi drug resistant murine leukemia L1210 cells.
|
[PMID: 9371238] |
| OCI-AML2 | IC50 |
100 nM
Compound: 39; CS1
|
Antiproliferative activity against human OCI-AML2 cells assessed as reduction in cell viability
Antiproliferative activity against human OCI-AML2 cells assessed as reduction in cell viability
|
[PMID: 38805939] |
| RPMI-8226 | IC50 |
0.018 μM
Compound: 1
|
Compound was tested for potency against human myeloma 8226 cells using MTT assay method.
Compound was tested for potency against human myeloma 8226 cells using MTT assay method.
|
[PMID: 9371238] |
| RPMI-8226 | IC50 |
9.1 μM
Compound: 1
|
Compound was tested for potency against human myeloma 8226 cells (40 fold resistant to doxorubicin).
Compound was tested for potency against human myeloma 8226 cells (40 fold resistant to doxorubicin).
|
[PMID: 9371238] |
| SW480 | IC50 |
0.09 μM
Compound: 1
|
Compound was tested for potency against human colon carcinoma SW 480 cells in a sulforhodamine B assay.
Compound was tested for potency against human colon carcinoma SW 480 cells in a sulforhodamine B assay.
|
[PMID: 9371238] |
| WiDr | IC50 |
0.79 μM
Compound: 1
|
Compound was tested for potency against human colon carcinoma WiDr cells in a sulforhodamine B assay.
Compound was tested for potency against human colon carcinoma WiDr cells in a sulforhodamine B assay.
|
[PMID: 9371238] |
In Vitro
Bisantrene promots DNase I cleavage at oligopurine-oligopyrimidine tracts and slightly reduces the cleavage activity at alternating purine-pyrimidine sequences[1].? Bisantrene is an inhibitor of [3H]uridine incorporation into RNA and [3H]thymidine incorporation into DNA[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 78186-34-2
-
Appearance Solid
-
Molecular Weight 398.46
-
Formula C22H22N8
-
Color Orange to red
-
SMILES
C12=CC=CC=C1C(/C=N/NC3=NCCN3)=C4C(C=CC=C4)=C2/C=N/NC5=NCCN5
-
Synonyms
CL216942
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
AI-based classification of anticancer drugs reveals nucleolar condensation as a predictor of immunogenicity. [Abstract]2024 Dec 20;23(1):275. PMID: 39702289 -
Nat Commun
Autophagy of the m6A mRNA demethylase FTO is impaired by low-level arsenic exposure to promote tumorigenesis. [Abstract]2021 Apr 12;12(1):2183. PMID: 33846348 -
Mol Cell
R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. [Abstract]2021 Mar 4;81(5):922-939.e9. PMID: 33434505 -
Anal Chem
Metal-Enhanced Aggregation-Induced Emission Strategy for the HIV-I RNA-Binding Ligand Assay. [Abstract]2022 Mar 22;94(11):4695-4702. PMID: 35258935 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Solvent & Solubility
In Vitro:
DMSO : 1 mg/mL (2.51 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Korean - KR (537 KB)
- Portuguese - PT (537 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sissi C, et al. DNA-binding preferences of Bisantrene analogues: relevance to the sequence specificity of drug-mediated topoisomerase II poisoning. Mol Pharmacol. 1998 Dec;54(6):1036-45. [Content Brief]
[2]. Yap HY, et al. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar;43(3):1402-4. [Content Brief]
[3]. Wang BS, et al. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene). Cancer Res. 1984 Jun;44(6):2363-7. [Content Brief]
[4]. Aksentijevich I, et al. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity. Clin Cancer Res. 1996 Jun;2(6):973-80. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5097 mL | 12.5483 mL | 25.0966 mL | 62.7416 mL |